News

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

LGM Pharma Expands Analytical Services

March 13, 2024

The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.

Software Advances Mass Customization for Cell and Gene Therapies

March 12, 2024

In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.

Cellares Set to Launch Good Manufacturing Practice–Compliant Cell Shuttle Manufacturing Platform

March 12, 2024

The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.

Bormioli Pharma’s Business Expands in United States

March 12, 2024

The European company has seen its business increase by 47% in North America.

Alliance for Building Better Medicine Receives NSF Award

March 11, 2024

The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.

EMA Validates Parallel Applications for Datopotamab Deruxtecan in Two Types of Cancer

March 08, 2024

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

Jacobs Announces Innovation Hub in Denmark

March 08, 2024

The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.

Europe's DARWIN EU Data Program Adds Capacity

March 08, 2024

EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.